THR-687, a Highly Selective RGD Integrin Inhibitor, for the Treatment of Diabetic Macular Edema: Preclinical, Phase 1 and Preliminary Phase 2 (Part A) Data

• Video
• Published 2022

See more

• On Demand Cases, Courses, and Papers